Beam Therapeutics (BEAM) Assets Average (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Assets Average data on file, last reported at $1.5 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.5 billion, up 15.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 15.22% YoY), and the FY2025 annual result was $1.3 billion, up 0.84% from the prior year.
• Assets Average rose to $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.5 billion in Q1 2026 and troughed at $1.1 billion in Q4 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average jumped 155.73% in 2022, then declined 17.27% in 2024.
• A 5-year view of Assets Average shows it stood at $1.3 billion in 2022, then climbed by 2.17% to $1.4 billion in 2023, then decreased by 17.27% to $1.1 billion in 2024, then grew by 22.73% to $1.4 billion in 2025, then increased by 6.08% to $1.5 billion in 2026.
• Business Quant data shows BEAM's Assets Average at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.